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What is already known:  
 CKD patients present alterations in mineral metabolism components including a decline 
in klotho protein expression  
 Recent studies point to klotho as a new anti-ageing factor with cardioprotective 
properties  
What this study adds: 
 Klotho deficiency alters systolic Ca2+ release and contractile function, and increases 
pro-arrhythmogenic diastolic Ca2+ leak    
 Recombinant klotho treatment prevents cardiac Ca2+ mishandling and RyR 
hypersensitivity in CKD   
Clinical significance:  
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Recombinant klotho is a promising new prophylactic strategy to reduce cardiac functional 






Summary (in 50 words)  
Klotho, named after the Greek goddess Klotho who spun the thread of life, is an ageing-
suppressing protein. Renal disease is a form of premature ageing with a diminution in klotho 
synthesis which courses with fatal cardiovascular events. We demonstrate that klotho 




Klotho is a membrane-bound or soluble protein originally identified as an age-suppressing 
factor and regulator of mineral metabolism. Klotho deficiency is associated with the 
development of renal disease, but its role in cardiac function in the context of uraemic 
cardiomyopathy is unknown.  
Experimental Approach We explored the impact of klotho on cardiac Ca2+ cycling. We 
analysed Ca2+ handling in adult cardiomyocytes from klotho-deficient (kl/kl) mice and from a 
murine model of 5/6 nephrectomy (Nfx). We also studied the effect of exogenous klotho 
supplementation, by chronic recombinant klotho treatment, or endogenous klotho 
overexpression, using transgenic mice overexpressing klotho (Tg-Kl), on uraemic 
cardiomyopathy. Hearts from Nfx mice were used to study Ca2+ sensitivity ryanodine receptor 
and its phosphorylation state.  
Key results 
Cardiomyocytes from kl/kl mice showed a decrease in the amplitude of intracellular Ca2+ 
transients and cellular shortening together with an increase in pro-arrhythmic Ca2+ events 
compared with cells from wild-type mice. Cardiomyocytes from Nfx mice exhibited the same 
impairment in Ca2+ cycling than kl/kl mice. Changes in Nfx cardiomyocytes were explained by 
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higher sensitivity of ryanodine receptors to Ca2+ and their increased phosphorylation at the 
calmodulin kinase type II and protein kinase A sites. Ca2+ mishandling in Nfx-treated mice was 
fully prevented by chronic recombinant klotho administration or transgenic klotho 
overexpression.  
Conclusions and Implications  
Klotho emerges as an attractive therapeutic tool to improve cardiac Ca2+ mishandling observed 
in uraemic cardiomyopathy. Strategies that improve klotho availability are good candidates to 
protect the heart from functional cardiac alterations in renal disease.  
 
Key words: Klotho, uraemic cardiomyopathy, chronic kidney disease, Ca2+ mishandling, 
ryanodine receptors.  
Abbreviations:  
BUN: Blood Urea Nitrogen; CaMKII: Ca2+/calmodulin-dependent protein kinase II; CKD: 
Chronic Kidney Disease; EF: Ejection fraction; FGF-23: Fibroblast Growth Factor-23; FGFR: 
Fibroblast Growth Factor Receptor; Hz: Hertz; Mhz: Megahertz; Nfx: 5/6 nephrectomy; PKA: 
Protein Kinase A; rKL: recombinant klotho; sKL: soluble klotho; SR: Sarcoplasmic Reticulum; 
SERCA: Sarcoplasmic Reticulum Ca2+-adenosine triphosphatase 2a; RyR: Ryanodine 
Receptor.    
 
Introduction 
Risk of cardiovascular disease increases as renal function declines (Go, Chertow, Fan, 
McCulloch & Hsu, 2004; Herzog et al., 2011), and cardiovascular disease is the major cause 
of mortality in patients with chronic kidney disease (CKD). Among the components of bone 
mineral metabolism, alterations in klotho protein and fibroblast growth factor (FGF)-23 axis 
seem to be important contributors to the high cardiovascular risk in this patient group 
(Gutiérrez et al., 2008; Isakova et al., 2018; Isakova et al., 2011). FGF-23 is a circulatory 
hormone that mainly targets the kidney, where it controls systemic phosphate homeostasis. The 
phosphaturic action of FGF-23 is dependent on renal expression of membrane-bound klotho, a 
powerful regulator of ageing and life-span (Kuro-o et al., 1997). Klotho is predominantly 
synthesised in the kidney where it binds to FGF receptors (FGFRs), increasing their affinity 
for FGF-23 and promoting urinary phosphate excretion (Urakawa et al., 2006). Klotho 
expression diminishes as renal function deteriorates, and this reduction might be responsible 
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for the resistance to FGF-23 observed along the course of CKD (Pavik et al., 2013). Membrane-
bound klotho can be shed by the action of secretases and released into circulation as a soluble 
form. Circulating soluble klotho (sKL) has several pleiotropic functions that are poorly 
understood, including an apparently cardioprotective action that is independent of FGF-23 and 
phosphate (Hu et al., 2017; Xie, Cha, An, Kuro-O, Birnbaumer & Huang, 2012; Xie, Yoon, 
An, Kuro-o & Huang, 2015). Accordingly, high soluble klotho levels are associated with a 
lower risk of developing cardiovascular disease and low soluble klotho levels are related to 
cardiac dysfunction, at least when advanced age is considered (Semba et al., 2011). Several 
recent clinical studies have shown that low circulating soluble klotho levels associate with 
elevated risk of cardiovascular mortality or hospitalisation due to cardiovascular events 
(including heart failure development, myocardial infarction or stroke) in patients with stable 
ischemic heart disease (Bergmark et al., 2019) or on hemodialysis (Memmos et al., 2019). 
Thus, there is a need to determine whether klotho can directly regulate cardiomyocyte function 
and cardiac rhythm in the setting of renal disease, and to elucidate the underlying mechanisms 
involved in the potential cardioprotective actions of klotho.  
The increased cardiovascular morbidity and mortality linked to renal dysfunction is due, at 
least in part, to the high prevalence of heart failure and arrhythmias in patients with CKD 
mainly those undergoing dialysis (Charytan et al., 2016; Verde et al., 2016; Wanner, Amann 
& Shoji, 2016). Indeed, cardiovascular deaths account for ~50% of all deaths in CKD, 
especially in patients on dialysis, which is chiefly due to fatal arrhythmias (Coll et al., 2018). 
Alterations in intracellular Ca2+ cycling, such as changes in Ca2+ release from the sarcoplasmic 
reticulum (SR) mediated by ryanodine receptor (RyR) channels in cardiomyocytes, are well 
documented mechanisms involved in cardiac dysfunction and arrhythmias (Bers, 2014; Nattel, 
Maguy, Le Bouter & Yeh, 2007). Cardiac contraction is triggered by an action potential that 
induces a small Ca2+ influx via sarcolemmal L-type Ca2+ (ICaL) channels, triggering a greater 
release of Ca2+ from the SR by RyR channels. This elevation in cardiomyocyte Ca2+ transients 
stimulates cardiomyocyte contraction (Bers, 2002). Relaxation is initiated when Ca2+ is 
pumped out from the cytosol by two chief mechanisms: 1) Ca2+ re-uptake to the SR by the Ca2+-
adenosine triphosphatase 2a pump SERCA (~92%),  and 2) Ca2+ extrusion to the extracellular 
medium by the Na+/Ca2+ exchanger NCX (~7%) (Bers, 2002). An increase in RyR channel 
sensitivity, evoking higher spontaneous diastolic SR-Ca2+ leak, is known to increase the risk 
of malignant arrhythmias (Navarro-García et al., 2019). Whether Ca2+ handling alterations also 
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occur in the context of CKD, and whether klotho could induce cardioprotection in this context 
by modulating intracellular Ca2+ handling remains unknown. 
Here, we used klotho-deficient (kl/kl) mice to question if klotho is necessary for correct 
cardiomyocyte function. Furthermore, we established a murine model of CKD by 5/6 
nephrectomy to test the hypothesis that strategies directed to improve klotho availability – 
supplied exogenously (recombinant) or endogenously enhancing its expression – could prevent 




Male C57BL/6J mice (20-23 g, 6 weeks of age; IMSR_JAX:000664) were purchased from 
Charles River Laboratories International Inc. (Wilmington, MA, USA; SCR_003792). Mice 
were bred and housed under specific pathogen-free conditions in the Experimental Animal 
Centre of Hospital Universitario 12 de Octubre, Madrid, Spain. All experiments were 
performed after approval of the Bioethical Committee Universidad Autónoma de Madrid; the 
animal protocol was approved by the General Direction of Agriculture and the Environment at 
the Environment Council of Madrid (PROEX 053/16) following of the guidelines for ethical 
NIH Guide for the Care and Use of Laboratory Animals and Guidelines for Ethical Care and 
Welfare (2013/175) of Experimental Animals of the European Union (2010/63/EU) and 
following the ARRIVE guidelines for reporting experiments involving animals (Kilkenny, 
Browne, Cuthill, Emerson & Altman, 2010; McGrath, Drummond, McLachlan, Kilkenny & 
Wainwright, 2010). Animals were maintained at controlled temperature (23-25ºC) on a 12-
hours light/dark cycle with ad libitum access to water and a standard diet (ROD14, Altromin 
Spezialfutter GmbH & Co. KG, Lage, Germany). Animals were housed in groups of 4 per cage 
of 553 cm2 by 20.8 cm depth (polysulfone cage type II L, SODISPAN, Madrid, Spain) with 
standard wood chip (ECO-PURE 7 Chips, Tapvei®, Estonia). All efforts were made to reduce 
the number of animals required to obtain reliable results and minimise the suffering of the 
animals based on the 3Rs rule of replacement, refinement, and reduction. The viability of the 
ventricular cardiomyocyte isolation process was established when the percentage of relaxed 
and rod-shaped cardiomyocytes in total cell count was equal or bigger than 70 % (Shioya, 
2007). No difference was observed in the viability of the cardiomyocyte isolation process 
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Experimental model of chronic kidney disease and treatments 
Mice underwent Sham or 5/6 nephrectomy (Nfx) surgery to induce CKD. Nfx was performed 
in a two-step procedure under isoflurane anaesthesia (1.5% v/v, isoflurane/oxygen). In the first 
step an abdominal incision was made, and the upper and lower poles of the left kidney were 
removed, leaving an intact segment around the hilum (experimental week 0). One week later, 
a dorsal incision was made and the right kidney was completely removed (Gagnon & 
Gallimore, 1988). Sham-operated mice followed the same protocol without the removal of the 
kidneys. Metoxicam (0.06 mL kg-1, s.c. single dose) was used as analgaesia after surgeries. 
After Sham or Nfx surgery mice were blindly randomized to receive either vehicle solution 
(0.9% sodium chloride) or murine recombinant klotho (rKL, at the dose of 0.01 mg kg-1 of 
weight per day). Mice were treated at the same hour in the morning every day for 6 weeks via 
intraperitoneal injection as described before (Hu et al., 2017). Macroscopic parameters were 
analysed in 16 Sham, 20 Nfx, 17 Sham+rKL and 22 Nfx+rKL mice. 10 mice in each group 
were used for biochemical parameters, 5-7 mouse hearts per group were used for ryanodine 
binding analysis and 5 mice per group were used for echocardiogram analysis. Cardiomyocytes 
obtained from 5 Sham, 6 Nfx, 5 Sham+rKL and 6 Nfx+rKL mice were used to Ca2+ handling 
analysis.  
Echocardiography 
Mouse hearts were visualized by echocardiography, using the Vivid Q ultrasound system (GE 
Healthcare), with a coupled linear sonar of 14 Mhz. A single investigator blinded to the 
experimental groups performed the analysis. Measurements were carried out with mice under 
isoflurane anaesthesia (1.5% v/v, isoflurane/oxygen) in order to keep a heart rate of about 400 
beats/minute. Body hair was shaved, and parasternal images of the short axis of the heart were 
obtained in a bidimensional mode (B), for anatomical visualization. Taking as a reference the 
papillary muscles, the functional analysis of cardiac contractility was carried out by an 
ultrasound M mode, to determine ejection fraction (EF) using cardiac analysis software. 
Klotho-hypomorphic and klotho-overexpressing mice 
Transgenic (Tg-Kl), and klotho hypomorphic (kl/kl) mice were kindly provided by Dr. Kuro-o 
and bred in our animal facilities.  
Male kl/kl mice (8 g of weight) and their +/+ littermates (20 g of weight) were used at 6-8 
weeks of age. Macroscopic parameters were analysed in 22 +/+ and 19 kl/kl mice. 10 mice in 
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each group were used for biochemical parameter analysis, and 5 mice per group were used for 
Ca2+ handling analysis.  
Tg-Kl 6-week-old mice with a weight between 20-22 g underwent Sham (Sham-Tg-Kl) or Nfx 
(Nfx-Tg-Kl) surgery as described before. Biochemical parameters were analysed in 5 Sham-
Tg-Kl and 8 Nfx-Tg-Kl mice, and 5 mice per group were used for Ca2+ handling analysis. 
Serum and urine biochemistry 
Plasma levels of phosphorus (Abcam, Cambridge, UK), urea and blood urea nitrogen (BUN) 
(BioAssays System, Hayword, CA), and FGF-23 (Immunotopics, Inc., San Clemente, CA) 
were measured by ELISA following the manufacturers’ instructions. Mouse soluble α-klotho 
assay kit (IBL International, Hamburg, Germany) was used to measure sKL in urine samples.  
Cardiomyocyte isolation 
Adult male mice (6–8-week-old +/+ or kl/kl, 14-week-old WT-Sham, Nfx, Sham+rKL or 
Nfx+rKL and Tg-Kl-Sham or Tg-Kl-Nfx, blindly selected) were anaesthetised with sodium 
pentobarbital-heparin (100 mg/kg, i.p.). Mice were sacrificed and hearts were rapidly removed 
and cannulated via the ascending aorta on a Langendorff perfusion system (Navarro-García et 
al., 2019; Ruiz-Hurtado et al., 2015). Hearts were retrograde perfused with calcium-free 
Tyrode’s solution supplemented with 0.2 mmol L-1 EGTA for 3 minutes followed by Tyrode’s 
solution containing 0.1 mmol L-1  CaCl2, 1 mg mL
-1  type II collagenase (Worthington, 
Lakewood, NY) and 1 mg mL-1  BSA for 3–4 minutes at room temperature. Digested hearts 
were filtered through a nylon mesh (250 μm) and centrifuged at 500 rpm for 3 minutes at room 
temperature. The pellet was re-suspended in Tyrode’s solution containing 0.5 mmol L-1 CaCl2 
and centrifuged again. Finally, the pellet was resuspended in Tyrode’s solution containing 1 
mmol L-1 CaCl2. Tyrode’s solution contained (in mM): 130 NaCl, 5.4 KCl, 0.4 NaH2PO4, 0.5 
MgCl2, 25 HEPES, 22 Glucose. The pH was adjusted to 7.4 with LiOH. 
Confocal Ca2+ images analysis.  
Isolated ventricular cardiomyocytes were loaded with the membrane-permeant fluorescent 
Ca2+ indicator Fluo-3 AM (5 μmol L-1; Invitrogen, Carlsbad, CA) for 30 min at room 
temperature. Line-scan Ca2+ images were obtained using confocal microscopy (Meta Zeiss 
LSM 510, objective w.i. 40×, n.a. 1.2) at the speed of 1.5 ms/line (1000 lines per image) with 
a pixel size of 0.07 µm for recording Ca2+ transients, Ca2+ sparks and Ca2+ wave images; while 
for caffeine and arrhythmia protocols, confocal images were obtained at a speed of 3 ms/line 
(10000 lines per image) for a total duration of 30 s. All Ca2+ images were corrected for the 
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background fluorescence. In a set of experiments, Fluo-3 loaded cells were placed in a field 
stimulation chamber with two parallel platinum electrodes and filled with Tyrode solution. 
Cells were allowed to settle at the bottom of the chamber and paced at 2 Hz with a pulse 
generator (CS-420, Cibertec) during 1-2 min to allow steady-state intracellular Ca2+ transients. 
Then, a line was selected always in parallel to the longitudinal cell axis to be able to measure 
the associated cell shortening; and Ca2+ imaging recordings were manually initiated with the 
time-lapse plug-in included in Zen 2009 Imaging Software (12.09, ZEISS).  
The amplitude of Ca2+ transients was calculated by averaging the fluorescence values in a 1.4 
µm frame over time. The amplitude of Ca2+ transients was estimated as F/F0, where F was the 
maximum value of fluorescence signal during electrical stimulation, and F0 was the basal 
fluorescence at rest at each position determined as the average of the 50 lowest values on the 
fluorescence transient. Moreover, ΔF/F0 was calculated using the following formula: 
ΔF/F0=(F-F0)/F0. SERCA function was indirectly estimated by the decay time constant of 
intracellular Ca2+ transients, termed Tau, which was obtained by fitting the descending phase 
of the fluorescence trace to a single exponential. K SERCA refers to the SR-dependent fraction 
of the rate constant of decay of the systolic Ca2+ transient and was measured by subtracting the 
rate constant of decay of the caffeine-evoked transients from that of the systolic Ca2+ transients 
(Bode, Briston, Overend, O'Neill, Trafford & Eisner, 2011). Cell shortening was measured as 
the difference of cardiomyocytes length between electrical stimulation and resting. Cell 
shortening was expressed as the percentage of cell’s shortening length. Cell shortening profiles 
were obtained offline by measuring the cell length from each line of Ca2+ transient images. SR 
Ca2+ load was estimated by perfusing cardiomyocytes with 10 mmol L-1 caffeine immediately 
after field-stimulation. Caffeine depletes the SR of Ca2+ stores. Caffeine-evoked Ca2+ 
transients’ amplitude was measured as peak F/F0 and was used to rate the global SR Ca
2+ load.  
In a set of experiments, spontaneous Ca2+ sparks were recorded in quiescent Fluo-3-loaded 
cardiomyocytes when electrical stimulation was stopped. Ca2+ sparks were considered as brief, 
located and rapid increments in Ca2+ fluorescence. Ca2+ sparks regions are determined as the 
sites where fluorescence signal increased at least 4-folds the standard deviation of the image 
fluorescence. This inclusion criteria limited the false events while detecting most sparks 
(Cheng et al., 1999). Spontaneous Ca2+ transients and Ca2+ waves in quiescent cardiomyocytes 
were detected as substantial spontaneous Ca2+ synchronic or non-synchronic release, 
respectively. The arrhythmic activity was measured as abnormal spontaneous Ca2+ transients 
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with automatic contractions in cardiomyocytes during a specific protocol, consisting of three 
cycles of 7 electric pulses followed by a recovery period.   
All Ca2+ images were processed and analysed offline using IDL (RSI) software and homemade 
routines. 
 
Ryanodine binding analysis 
[3H]ryanodine binding experiments were performed with left ventricle homogenates from 
individual hearts as described (de Alba-Aguayo et al., 2017). Specific binding was defined as 
the difference between the binding in the absence (total binding) and presence (non-specific 
binding) of 20 μM unlabelled ryanodine. The incubation medium contained (in mM): KCl 200, 
HEPES 20, EGTA-K salt 1, pH 7.2 with KOH. CaCl2 was added as necessary to establish free 
Ca2+ at 100 nM (equivalent to diastolic Ca2+ concentration) and 10 µM (equivalent to systolic 
Ca2+ concentration). Ca2+-EGTA ratios were calculated using the WEBMAXCLITE program 
v1.15 (https://web.stanford.edu/~cpatton/webmaxc/webmaxclite115.htm). Data analysis was 
performed using Origin (v8.1; OriginLab Corporation, Northampton, MA, USA).  
Western blotting 
Immunoblotting analysis complies with the recommendations on immunoblotting and 
immunohistochemistry in pharmacology (Alexander et al., 2018). Hearts were homogenised in 
400 µL of homogenisation buffer (0.05 M Tris, 0.32 M sucrose, 0.5% CHAPS, 0.5 µM okadaic 
acid, and the protease inhibitors 0.1 mM PMSF, 12 µM leupeptin, 0.2 µM aprotinin and 0.5 
mM benzamidine), and the pH was adjusted to 7.0. Homogenates were centrifuged at 4500 rpm 
for 10 minutes at 4ºC. Supernatants were collected in microtubes and 20 µg of total protein was 
used for western blotting. Samples were resuspended in SDS-PAGE loading buffer (4× 
Laemmli Sample Buffer; Bio-Rad, Hercules, CA, USA) with 10% β-mercaptoethanol, and 
were heated for 5 minutes at 90ºC. Samples were loaded on 4–20% SDS-PAGE gradient gels 
(CriterionTM TGXTM Precast Gels, Bio-Rad). Proteins were electrophoretically transferred onto 
PVDF membranes (Trans-Blot® TurboTM Midi Format, 0.2 µm PVDF, Bio-Rad) on a semi-dry 
transfer system (Trans-Blot SD, Bio-Rad) at 2.5 A, 25 V for 10 minutes. Membranes were 
blocked with 5% BSA, TBS-T20 buffer (50 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-
20). Fresh antibodies solutions were used for immunoblotting. Antibodies used were as 
follows: Rabbit polyclonal IgG anti-phosphoRyR Ser2814 (AB_2617055) at 1:2000 dilution and 
rabbit polyclonal IgG anti-phosphoRyR Ser2030 at 1:2000 dilution (A010-31 and A010-32, 
 
 
This article is protected by copyright. All rights reserved. 
respectively, both from Badrilla, Leeds, UK), mouse monoclonal IgG1  anti-RyR 
(AB_2183054) at 1:2500 dilution and mouse monoclonal IgG1 anti-GAPDH (AB_2536381) 
at 1:400,000 dilution (MA3-916 and AM4300, respectively, both from Thermo Fisher 
Scientific, Waltham, MA, USA). HRP-conjugated secondary antibodies used were: anti-mouse 
IgG kappa (AB_2687626) at 1:5000 dilution and mouse anti-rabbit (AB_628497) at 1:5000 
dilution (sc-516102 and sc-2357, respectively, both from Santa Cruz Biotechnology, Dallas, 
TX, USA). 
RNA isolation and Quantitative Real-Time PCR 
Total RNA was isolated from mouse hearts using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). Quality and quantity of RNA were assessed with NanoDrop One Microvolume UV-
Vis Spectrophotometer (Thermo Fischer Scientific, Waltham, MA) and 2 μg of RNA was 
reverse-transcribed to cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). Quantitative RT-PCR was performed using FastStart Essential 
DNA Green Master (Roche, Basel, Switzerland) in 10 µl total reaction volume on a 
LightCycler® 480 II (Roche, Basel, Switzerland) at optimized thermocycling settings. Relative 
gene expression was normalized to the ribosomal housekeeping gene 36b4 (RPLP0) and 
evaluated using the 2-Ct method. The primer sequences (5´-3´) for SERCA2a (Atp2a2), 36b4, 
collagen I (col1a1), collagen III (col3a1) and atrial natriuretic peptide (Nppa) were as follows: 
Atp2a2-Forward TAAATGCCCGCTGTTTTGCT; Atp2a2-Reverse 
TTGTCATCTGCCAGGACCAT; 36b4-Forward AGATGCAGCAGATCCGCAT; 36b4-
Reverse GTTCTTGCCCATCAGCACC; col1a1-Forward AATGGCACGGCTGTCTGCGA; 
col1a1-Reverse AGCACTCGCCCTCCCGTCTT; col3a1-Forward 
CTGTAACATGGAAACTGGGGAAA; col3a1-Reverse  
CCATAGCTGAACTGAAAACCACC; Nppa-Forward CTGGGACCCCTCCGATAGAT; 
Nppa-Reverse  CACTCTGGGCTCCAATCCTG.  
Drugs and reagents  
EGTA, sodium chloride, potassium chloride, monosodium phosphate, magnesium chloride, 
HEPES, glucose, lithium hydroxide, potassium hydroxide, leupeptin, aprotinin, benzamidine, 
β-mercaptoethanol, Tween 20 and caffeine have been purchased from Sigma-Aldrich (Milan, 
Italy). Isoflurane has been purchased from Abbie Spain (Madrid, Spain). CHAPS has been 
purchased from GE Healthcare (Chicago, IL, USA). Okadaic acid-K salt has been purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA). 4x-Laemli Sample Buffer and TBS have 
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been purchased from Bio-Rad (Hercules, CA, USA). Pentobarbital has been purchased from 
Vetoquinol (Madrid, Spain). Heparin has been purchased from ROVI (Madrid, Spain).  All the 
reagents have been dissolved in dH2O when it was necessary.  
Statistics 
Group size estimation was designed to be equal considering 90% power. Inferential statistics 
were used to summarise the data from ≥5 animals per group. Any inequalities between 
experimental groups were exclusively due to the assumed animal losses related to the specific 
surgery (5/6 nephrectomy) used in the study. The number of animals used in this study was 
based on power calculation and was a total of 122. The mouse was considered as the 
experimental unit for echocardiography, western blotting, and ryanodine binding analyses and 
the whole heart was used for measurement and referred as “N”. For all Ca2+ handling studies, 
the cardiomyocyte was considered as the experimental unit and referred as “n” after assessing 
the absence of false-positives and independence of the obtained data and the absence of 
clustering estimated by the intra-cluster correlation coefficient (ICC) tests for all cellular data 
sets and experimental models used.  For Ca2+ handling studies, both cell number (n) and animal 
number (N) are shown and cardiomyocytes were isolated from at least 5 mice in each 
experiment. Data are presented as mean ± SEM. The data and statistical analysis comply with 
the recommendations on experimental design and analysis in pharmacology (Curtis et al., 
2015). The data that support the results obtained in this study are available upon reasonable 
request from the corresponding author. Statistical significance was evaluated using paired 
Student’s test, χ2 test or ANOVA with Newman-Keuls multiple comparison tests when 
appropriate (only with homogeneity and if F was significant). The Kolmogorov-Smirnov test 
was used to determine the Gaussian distribution of the values. All p-values are two-tailed and 
p-values <0.05 were considered statistically significant. All analyses were performed using 
GraphPad Prism v6.0 (GraphPad software Inc., San Diego, CA; SCR_002798) or Origin Pro 





Klotho deficiency alters intracellular Ca2+ handling and cardiomyocyte shortening, and 
increases pro-arrhythmogenic Ca2+ events 
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To examine whether klotho is needed for a correct cardiac function related to cardiomyocyte 
Ca2+ handling, we used an experimental model of uraemia characterised by deficiency in 
klotho, the klotho-hypomorphic (kl/kl) mouse. Macroscopic analysis showed that kl/kl mice 
were significantly smaller than their littermates +/+ (Figure 1A, Table 1). Similarly, heart and 
kidney weights were significantly lower in kl/kl mice than in +/+ mice (Table 1). Heart weight 
to body weight ratio (HW/BW) was significantly higher in kl/kl mice than in +/+ mice (Table 
1). However, this increase in HW/BW ratio was not accompanied by signs of cellular 
hypertrophy in kl/kl mice, since cardiomyocyte area was significantly smaller in kl/kl mice than 
in +/+ mice (1471 ± 39.7 vs. 2428 ± 67.7 µm2, P<0.05). We also measured mRNA expression 
levels of the atrial natriuretic peptide (ANP, Nppa) by quantitative RT-PCR in hearts from kl/kl 
and +/+ mice as a classic marker of cellular hypertrophy, finding Nppa gene expression not 
different between groups (1.037 ± 0.13 for +/+ vs. 0.974 ± 0.07 for kl/kl, arbitrary units, 
P=0.674). Moreover, to assess whether the absence of klotho expression could be accompanied 
by myocardial fibrosis development, collagen I and III levels were also analysed through 
col1a1 or col3a1 gene expression levels. Kl/kl mice showed reduced levels of collagen I and 
III than +/+ mice (1.008 ± 0.06 vs. 0.267 ± 0.03 arbitrary units, P<0.05 for col1a1; 1.162 ± 
0.03 vs. 1.014 ± 0.08, P<0.05 for col3a1). Therefore, the increment in HW/BW ratio in kl/kl 
mice was not due to cardiomyocyte hypertrophy or cardiac fibrosis development. On the other 
hand, as expected, kidney function was impaired in kl/kl mice, as reflected by the significant 
increase in the levels of urea, BUN and FGF-23 relative to +/+ littermates (Table 1). However, 
no differences in phosphates serum levels were observed between both groups (Table 1), 
possibly as consequence of the phosphaturic action induced by the very high FGF-23 levels. 
We next analysed intracellular Ca2+ handling in cardiomyocytes isolated from both 
experimental groups. We studied systolic Ca2+ release through electrically-evoked intracellular 
Ca2+transients. Figure 1B shows representative line-scan Ca2+ images (bottom panels) and 
fluorescence profiles (upper panels) obtained during electric field stimulation at 2 Hz, 
corresponding to +/+ (left panel) and kl/kl (right panel) cardiomyocytes. Similar differences in 
the amplitude of Ca2+ transients (F/F0) were found between +/+ vs. kl/kl mice analysed by cells 
or by hearts (3.46 ± 0.11 vs. 1.84 ± 0.05 or 3.46 ± 0.18 vs. 1.84 ± 0.08, respectively). 
Intracellular Ca2+ transients amplitude (F/F0) was significantly lower in kl/kl cells than in +/+ 
cells (Figure 1C). In addition, cardiomyocytes from kl/kl mice showed a decrease in ΔF/F0, 
indicating a significant decrease in the global intracellular Ca2+ transient in kl/kl cells 
(Supplemental Figure S1). The time constant of Ca2+ transients decay, Tau, was significantly 
longer in kl/kl cells than in +/+ cells (Figure 1D). This is also illustrated in the representative 
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fluorescence profiles normalised by the peak of Ca2+ transients from +/+ and kl/kl cells 
(Supplemental Figure S2), indicating that the SERCA pump was working slower in kl/kl 
cardiomyocytes. Because this slower time decay of Ca2+ transients could indicate a worse SR-
Ca2+ reuptake by SERCA, we analysed the cardiac mRNA levels of SERCA2 in hearts from 
+/+ and kl/kl mice. As shown in Supplemental Figure S3, SERCA2 expression was 
significantly reduced in the hearts of kl/kl mice compared to +/+ mice. Moreover, K SERCA, 
the SR-dependent contribution of the rate constant of decay of the systolic Ca2+ transient, was 
also determined by subtracting the rate constant of decay of the caffeine-evoked transients from 
that of the systolic Ca2+ transients. K SERCA was significantly lower in kl/kl mice than in +/+ 
mice (Supplemental Figure S4), supporting a diminished SERCA-mediated Ca2+ reuptake. We 
next addressed whether the decrease in systolic Ca2+ release impaired contractile function. 
Representative cell shortening profiles of cardiomyocytes are shown in Figure 1E. Cell 
shortening was significantly lower in kl/kl cells than in +/+ cells (Figure 1F). Changes in 
systolic Ca2+ release can be related to alterations in SR-Ca2+ load. To study this, we applied 
caffeine to isolated Fluo-3-loaded cardiomyocytes to empty the SR of Ca2+. Representative 
line-scan images of caffeine-evoked Ca2+ transients are shown in Figure 2A. Results showed 
that the amplitude (F/F0) of caffeine-evoked Ca
2+ transients was significantly lower in kl/kl 
cardiomyocytes than in cells from their littermates (Figure 2B). Caffeine-evoked Ca2+ transient 
decay was not different in cardiomyocytes from kl/kl mice respect +/+ mice, suggesting no 
alterations in Ca2+ extrusion through the NCX (Supplemental Figure S5). 
We next analysed whether the change in SR-Ca2+ load was related to alterations in diastolic 
Ca2+ leak. Representative line-scan images of Ca2+ sparks recordings are shown in Figure 2C. 
We observed a significantly higher frequency of Ca2+ sparks in kl/kl cardiomyocytes than in 
+/+ cells (Figure 2D). Spontaneous calcium release (SCR) was also studied during diastolic 
recordings; spontaneous intracellular Ca2+ transients and Ca2+ waves were considered forms of 
SCR (Figure 2E, left and right panel, respectively). kl/kl cardiomyocytes had a significantly 
higher prevalence of SCR than +/+ cells (Figure 2F). Finally, we measured pro-arrhythmogenic 
Ca2+ events in cardiomyocytes isolated from both groups of mice. Figure 2G shows 
representative line-scan images of the pacing protocol. Pro-arrhythmogenic Ca2+ release was 
significantly higher in kl/kl cardiomyocytes than in +/+ cells (Figure 2H). 
Chronic recombinant klotho administration prevents the cardiac dysfunction and 
impaired systolic Ca2+ release induced by experimental chronic kidney disease 
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We next employed a classical model of CKD (5/6 nephrectomy) to conduct a detailed analysis 
of the functional cardiac consequences in a uraemic context. Moreover, based on previous 
evidence demonstrating the cardioprotective action of exogenous klotho supplementation (Hu 
et al., 2017; Nowak et al., 2014) and after confirming that Nfx mice have significantly 
decreased klotho levels compared with Sham mice (Supplemental Figure S6) we analysed the 
effect of recombinant klotho (rKL) administration on cardiac function and Ca2+ cycling. The 
experimental design is shown in Figure 3A. Macroscopic analysis revealed that Nfx induced 
overall body weight loss independently of subsequent treatment (Table 2). Kidney weight was 
also significantly lower in Nfx mice than in Sham mice, both in vehicle- and rKL-treated mice. 
No differences were observed in heart weight or HW/BW ratio among groups (Table 2). No 
evidence of cellular hypertrophy was observed in CKD mice as demonstrated by similar 
cardiomyocyte area (3192 ± 93.2 vs. 3187 ± 92.7; P=0.969) and ANP expression levels (1.170 
± 0.51 vs. 0.300 ± 0.05; P=0.175) between Sham and Nfx mice. To assess whether uremic 
cardiomyopathy induces myocardial fibrosis development, collagen I and III levels were 
analysed through col1a1 or col3a1 expression levels by quantitative PCR in hearts from Sham 
and Nfx mice. No differences were detected between Sham and Nfx mice (1.031 ± 0.13 vs. 
1.136 ± 0.11 arbitrary units, P=0.577 for col1a1; 1.058 ± 0.18 vs. 1.29 ± 0.11, P=0.338 for 
col3a1). Therefore, no signal of cardiac hypertrophy or fibrosis was detected in Nfx mice. 
Kidney function was impaired in Nfx mice, as demonstrated by significantly higher levels of 
plasma urea and BUN in the mice that underwent Nfx versus Sham mice (Table 2). These 
parameters remained elevated in rKL-treated Nfx mice, indicating that chronic rKL treatment 
does not recover renal function. FGF-23 levels were significantly elevated in Nfx mice, and 
also in Nfx animals chronically treated with rKL. By contrast, phosphorus levels were similar 
in all groups, likely due to the compensatory and rapid phosphaturic action evoked by the high 
FGF-23 levels. EF was measured by echocardiography as indicator of in vivo left ventricle 
global systolic function. EF was significantly reduced in Nfx compared with Sham mice, 
whereas Nfx treated with rKL for 6 weeks exhibited significantly improved EF than Nfx treated 
with vehicle, being not different than Sham+rKL mice (Figure 3B). Electrically-evoked Ca2+ 
transients of cardiomyocytes were studied under field stimulation of 2 Hz. Regarding 
contractile function, representative cell shortening profiles are shown for all groups in Figure 
3C, and we observed a significant decrease in cardiomyocyte shortening in Nfx compared with 
Sham cells (Figure 3D). Whereas no effect of rKL was found in Sham cells for shortening, 
Nfx+rKL cells showed a significant increase in cell contraction compared with vehicle-treated 
Nfx cardiomyocytes (Figure 3C, D). Figure 3E shows representative line-scan images (bottom 
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panels) and fluorescence profiles (upper panels) corresponding to intracellular Ca2+ transients 
in all experimental groups. Similar differences in the amplitude of Ca2+ transients (F/F0) were 
found between Sham and Nfx mice analysed by cells or by hearts (3.04 ± 0.12 vs. 2.11 ± 0.06 
or 3.18 ± 0.32, 2.12 ± 0.14, respectively). Ca2+ transients amplitude (F/F0) was significantly 
lower in Nfx cells than in Sham cells and was significantly higher in rKL-treated Nfx cells than 
in vehicle-treated Nfx cells (Figure 3F). Moreover, longer Tau values observed in Nfx cells 
(Figure 3G) indicate an impairment in SERCA function, which was also evident in the 
fluorescence profiles normalised to the peak of Ca2+ transients obtained from Sham versus Nfx 
cells (Supplemental Figure S7). Similarly, K SERCA was significantly lower in Nfx mice than 
in Sham mice (Supplemental Figure S8). rKL treatment prevented the increase in Tau (Figure 
3G). No differences were found for Tau in Sham+rKL and Nfx+rKL cardiomyocytes (Figure 
3G). Thus, chronic rKL treatment prevents the cardiac dysfunction and impairment in cell 
shortening observed in Nfx cardiomyocytes.  
Increased diastolic Ca2+ leak induced by experimental chronic kidney disease is prevented 
by recombinant klotho administration   
We evaluated SR-Ca2+ load in experimental CKD and the effect of rKL treatment. Figure 4A 
shows representative line-scan images of caffeine-induced Ca2+ release in each experimental 
group. CKD development led to a significant decrease in caffeine-evoked Ca2+ transient 
amplitude (F/F0) (Figure 4B) and this was partially prevented in rKL-treated Nfx mice (Figure 
4B). We tested whether the diastolic Ca2+ leak could be involved in the decreased SR-Ca2+ 
content evident in CKD. We next analysed the diastolic Ca2+ leak by measuring Ca2+ spark 
frequency and SCR. Figure 4C shows line-scan examples of Ca2+ spark recordings in the 
different groups of cardiomyocytes. Ca2+ spark frequency was significantly higher in Nfx 
cardiomyocytes than in Sham cardiomyocytes (Figure 4D). This increase was not observed in 
cardiomyocytes from Nfx mice treated with rKL (Figure 4D). We also analysed diastolic SCR 
in the form of Ca2+ waves (Figure 4E, left panel) and spontaneous Ca2+ transients (Figure 4E, 
right panel). The occurrence of SCR was 1.8-fold higher in Nfx cardiomyocytes (as Ca2+ spark 
frequency shown in Figure 4D) than in Sham cardiomyocytes (Figure 4F). However, chronic 
rKL treatment in Nfx mice prevented the increase of cardiomyocytes with SCR: 4% in rKL-
treated Nfx mice versus 20% in vehicle-treated Nfx mice (Figure 4F), which was even lower 
than that from Sham or rKL-treated Sham mice (12%, Figure 4F).  
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Chronic recombinant klotho treatment prevents pro-arrhythmogenic Ca2+ events, RyR 
hyperactivity and phosphorylation promoted by experimental chronic kidney disease 
We examined for the presence of arrhythmic behaviour dependent on Ca2+ cycling alterations 
during electrical pacing in the experimental CKD model. Figure 5A shows representative line-
scan Ca2+ images of ventricular cardiomyocytes from Sham or  Nfx mice treated or not with 
rKL and exposed to trains of electrical stimulation. When compared with Sham, Nfx 
cardiomyocytes presented a significant increase of automatic Ca2+ transients triggering 
automatic contractions between electrical pulses and after electrical pacing, and this was 
prevented by rKL treatment (Figure 5B). Given these findings, we next assessed whether 
alterations in RyR sensitivity could explain the arrhythmic behaviour in experimental CKD. 
Considering that ryanodine binds only to open RyRs, we determined the levels of functionally-
active RyRs in equivalent systolic and diastolic Ca2+ conditions in vitro. During the systolic 
Ca2+ recordings, we found a significant 2.9-fold increase in [3H]-ryanodine binding in Nfx 
hearts (Figure 6A) and this activity was effectively decreased by rKL, although it did not reach 
the levels in Sham animals, suggesting that additional mechanisms (i.e., SR-Ca2+ load) 
participate in decreasing the activity of RyRs. During diastolic Ca2+ recordings, Nfx hearts 
showed a significant 3.2-fold increase in the binding of [3H]-ryanodine at 100 nM free [Ca2+] 
(Figure 6B) and again rKL treatment reduced the Ca2+ sensitivity of RyRs in Nfx hearts (Figure 
6B). As Nfx did not alter total RyR protein expression levels (Figure 6C and D upper panels), 
the results indicate that RyRs from Nfx hearts are more sensitive to Ca2+. To determine the 
mechanism involved in RyR hyperactivity, we examined the phosphorylation status of cardiac 
RyR at two serine residues: Ser2030, key phosphorylation site of protein kinase A (PKA), and 
Ser2814, the specific phosphorylation site for Ca2+/calmodulin-dependent protein kinase II 
(CaMKII). RyR phosphorylation at Ser2030 and Ser2814 was significantly higher in extracts from 
Nfx mice than from Sham mice (Figure 6C and D). This increased phosphorylation for Ser2030 
and Ser2814 was not observed in Nfx mice treated with rKL, where basal levels of 
phosphorylation were similar to those of Sham mice.  
Klotho overexpression protects against cardiomyocyte contractile dysfunction and pro-
arrhythmic Ca2+ events in chronic kidney disease but does not eliminate renal damage  
We used Tg-Kl mice to examine the cardioprotective role of endogenous klotho overexpression 
in a uraemic context. Serum levels of BUN were significantly higher in Tg-Kl mice subjected 
to Nfx than Sham-Tg-Kl mice (Figure 7A). No differences were observed in serum phosphorous 
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levels between both groups (Figure 7B), but serum FGF-23 levels were significantly higher in 
Nfx-Tg-Kl mice than in Sham-Tg-Kl mice (Figure 7C). Analysis of Ca2+ cycling in isolated 
cardiomyocytes from both groups revealed no differences in Ca2+ spark frequency (Figure 7D), 
SCR (Figure 7E), SR Ca2+ load (Figure 7F), intracellular Ca2+ transients (Figure 7G) or cell 
shortening (Figure 7H) between them. Overall, these results show that endogenous klotho 
overexpression protects against Ca2+ cycling alteration preventing contractile dysfunction and 
diastolic pro-arrhythmogenic Ca2+ release in Nfx mice. 
Discussion  
Klotho was initially discovered as an aging-suppressing gene in mice that extends lifespan 
when overexpressed (Kuro-o et al., 1997). Klotho is expressed mainly in the kidney and is 
composed of a very short intracellular domain, a transmembrane domain and a large 
extracellular domain that is susceptible to ectodomain shedding, resulting in two forms, 
membrane and secreted or sKL (Kuro-o, 2011). In the kidney, membrane klotho acts as a co-
receptor for FGF-23, increasing the affinity of FGFRs for FGF-23-mediated phosphaturic 
action (Urakawa et al., 2006). sKL is a humoral factor with pleiotropic functions, including a 
cardioprotective action through the regulation of ion channels (Xie, Cha, An, Kuro-O, 
Birnbaumer & Huang, 2012) that is independent of FGF-23 and phosphate (Xie, Yoon, An, 
Kuro-o & Huang, 2015). CKD is considered a klotho-deficient state (Asai et al., 2012; Kuro-
O, 2011). CKD courses with premature aging and is considered a global health concern due to 
the high prevalence, around 10% in the general population (Coresh et al., 2007). At 
experimental level, it has been described that models of premature aging, as klotho 
hypomorphic mice, develop early-stage CKD. In addition, other authors have recently 
described that uremic environment increases with aging in the experimental CKD model 
(Heveran et al., 2019). However, no studies have described overlapping effects of CKD and 
aging on cardiac function. Cardiac dysfunction and fatal arrhythmias, in many cases 
asymptomatic ventricular arrhythmias, are the leading causes of mortality in patients with 
CKD, especially in those with end-stage renal disease (Banerjee, 2016; Verde et al., 2016). 
However, the underlying mechanisms involved in this cardiorenal interaction remain enigmatic 
and clinicians remain uncertain about how to reduce the burden of cardiovascular events in 
CKD.  
Our study provides the first demonstration, to our knowledge, that experimental uraemia 
induced by klotho deficiency or nephrectomy with reduced klotho levels is linked to a strong 
defect in Ca2+ handling, characterised by decreased systolic Ca2+ release and contractile 
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dysfunction and increased diastolic pro-arrhythmogenic Ca2+ release and leak accompanied by 
RyR hyperactivity. Our data also support the concept that preserving klotho availability, 
exogenously using prophylactic rKL chronic treatment or endogenously by enhancing klotho 
expression, could be a potential therapeutic strategy to protect the heart from the uraemic 
environment, including alterations in intracellular Ca2+ cycling that trigger contractile 
dysfunction and pro-arrhythmic mechanisms such as the hyperactivation of RyRs observed in 
CKD (Graphical Abstract). Our results show an increase in RyR activity in Nfx mice with 
higher spontaneous diastolic Ca2+ release and a diminution in SR-Ca2+ load. Both mechanisms 
are known to be associated with cardiac dysfunction and the predisposition to arrhythmias. The 
decrease in systolic Ca2+ release accompanied by a worsened contractile response, concomitant 
with extra-contractions and Ca2+ leak in the form of Ca2+ sparks and waves during diastole, 
were pro-arrhythmic Ca2+ events in cardiomyocytes from kl/kl and CKD mice. Furthermore, 
we identified a CKD-related increase in RyR phosphorylation as an underlying molecular 
explanation for the high RyR activity. Accordingly, RyR was robustly phosphorylated at its 
PKA (3-fold higher) and CaMKII (5-fold higher) sites in CKD mice. Similar results of PKA- 
and CaMKII-mediated RyR phosphorylation and its relationship with the predisposition to 
trigger fatal ventricular arrhythmias have also been found in experimental models of heart 
failure (Grimm et al., 2015; Xiao et al., 2005). This post-translational RyR modification of 
increased phosphorylation can be explained by the higher Ca2+ sensitivity of RyR at systolic 
and diastolic Ca2+ concentrations in CKD mice, which was prevented by rKL administration. 
Dhindwal et al.  proposed that phosphorylation induces RyR to adopt a protein conformation 
that requires less energy for the transition to the open state (Dhindwal et al., 2017). Therefore, 
a more flexible RyR conformation might exist when the phosphorylation state is significantly 
increased as in CKD mice in both phosphorylation sites (Ser2030 and Ser2814). Moreover, a 
similar increase in Ca2+ sensitivity has been observed in ventricular arrhythmia in experimental 
catecholaminergic polymorphic ventricular tachycardia (Fernández-Velasco et al., 2009). 
Gender-related differential activation of PKA and CaMKII pathways exists in rodent hearts 
also under pathological conditions (Bell et al., 2015; Parks, Ray, Bienvenu, Rose & Howlett, 
2014). For example, in diabetic cardiomyopathy the contribution of PKA- and CaMKII-
dependent pathways are less relevant in females than in male mice with a significant diminution 
of PKA- and CaMKII-induced RyR phosphorylation sites correlating with decreased spark-
mediated calcium leak in female mice (Delgado, Gomez, Samia El Hayek, Ruiz-Hurtado & 
Pereira, 2019; Pereira, Ruiz-Hurtado, Rueda, Mercadier, Benitah & Gómez, 2014). Thus, it 
would be very likely that these pathways could be also less active in female than in male mice 
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in the setting of uremic cardiomyopathy. However, in our study female mice were not 
contemplated to avoid the potential cardioprotective effects mediated by oestrogens which 
could be overlapping the klotho-mediated cardioprotective actions in experimental conditions 
of CKD. Future experimental studies are needed to corroborate the oestrogens contribution to 
the Ca2+ mishandling observed under uremic cardiomyopathy conditions. 
This study has several potential clinical and therapeutic applications for renal patients. First, 
our results show that decreased klotho availability, together with the presence of 
pathologically-elevated FGF-23 levels, might be a warning sign for increased risk of 
developing arrhythmic events in patients with CKD. Supporting this idea, several studies have 
previously shown that FGF-23 exposure alters cardiac contractility and Ca2+ handling in 
isolated adult ventricular cardiomyocytes (Navarro-García et al., 2019; Touchberry et al., 2013) 
and in HL-1 atrial cells (Kao et al., 2014). These findings support the notion that systemic 
elevation of FGF-23 likely has deleterious and direct effects on heart function in the complex 
pathological setting of uraemic cardiomyopathy (Faul, 2018). However, in the clinical setting 
further studies are still needed to decode whether FGF-23 itself is an independent uremic factor 
able to play a relevant role in the cardiac events accompanying the decline of renal function. 
Accordingly, a logical experimental approach would be the use of FGF-23 blocking antibodies 
as the most direct strategy to inhibit FGF-23 actions in the uraemic context. Yet, in a preclinical 
model of CKD, rats treated with a neutralizing FGF-23 antibody presented elevated systemic 
serum phosphate and developed severe cardiovascular complications (Shalhoub et al., 2012). 
Thus, the key point would be not to fully suppress FGF-23 actions, such as the physiological 
phosphaturic action, but only to block its damaging actions on the heart. The second application 
would involve exogenous klotho administration as a therapeutic option to block the deleterious 
FGF-23 actions on the heart. Klotho is emerging as a potential cardioprotective factor for 
uraemic cardiomyopathy. Indeed, klotho protects against vascular calcification in human (Lim 
et al., 2012) and experimental models (Hu et al., 2011) of CKD. Moreover, sKL deficiency in 
CKD seems to render the myocardium more susceptible to stress-induced injury (Xie, Cha, An, 
Kuro-O, Birnbaumer & Huang, 2012). Similarly, some authors have proposed that FGF-23 
induces cardiac toxicity only when serum levels of sKL are reduced in CKD (Hu et al., 2015), 
whereas other authors posit that klotho prevents uraemic cardiomyopathy by a direct effect on 
cardiomyocytes independently of FGF-23 and phosphates (Xie, Yoon, An, Kuro-o & Huang, 
2015). Nevertheless, clinical studies on the predictive value of klotho have produced 
conflicting results, with some reporting that plasma sKL levels did not predict cardiovascular 
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events or death in a large CKD cohort (Seiler et al., 2013), while others demonstrated a clear 
association between preserved sKL levels and reduced cardiovascular morbidity and mortality 
in dialysis-dependent CKD (Hu et al., 2011). The idea that sKL could function as a decoy of 
FGF-23 actions in the heart is in agreement with our results. Thus, we observed a 
cardioprotective effect of rKL administration on preventing contractile dysfunction and 
diastolic Ca2+ leak related to pro-arrhythmic events in cardiomyocytes from Nfx mice. In this 
respect, klotho has been shown to produce beneficial cardiac actions on ionic channels, 
including the downregulation of transient receptor potential cation channel 6 (TRPC6) in 
conditions of cardiac hypertrophy (Xie, Cha, An, Kuro-O, Birnbaumer & Huang, 2012; Xie, 
Yoon, An, Kuro-o & Huang, 2015). However, in physiological conditions, the contribution of 
TRPC6 channels to the total Ca2+ entry in cardiomyocytes is small and is higher in conditions 
of cardiac hypertrophy. In the present study, we found no evidence of cardiac morphology 
changes such as hypertrophy or fibrosis in klotho hypomorphic mice and mice after 6 weeks 
of 5/6 nephrectomy. Kl/kl mice showed an increase in HW/BW ratio that was not accompanied 
by an increase in cardiomyocyte area, or ANP and collagen expression as specific markers of 
cellular hypertrophy or fibrosis, respectively. A possible explanation for these results is that 
klotho hypomorphic mice showed reduced BW compared to +/+ mice; and they also present 
an important growth retardation affecting all organs, which could explain the reduced 
cardiomyocyte areas or collagen levels compared to their +/+ littermates. Besides the absence 
of klotho expression also induces important ectopic calcification in arterial walls and cardiac 
muscle (Kuro-o et al., 1997; Yoshida, Fujimori & Nabeshima, 2002). All these facts might 
favour a higher HW/BW ratio than that expected for its body weight and animal size. Therefore, 
these results support the conclusion that Ca2+ mishandling observed in kl/kl mice is not due to 
cardiomyocyte hypertrophy or deleterious remodelling development, though the influence of 
systemic calcaemia and alterations in vitamin D homeostasis in this klotho mutant mice 
(Yoshida, Fujimori & Nabeshima, 2002) could not be discarded; specially on the elevated 
diastolic Ca2+ release and pro-arrhythmic events of kl/kl cardiomyocytes. 
There is a general statement that the experimental CKD model shows a compromised EF and 
cardiac dysfunction in mice (Bro, Bollano, Brüel, Olgaard & Nielsen, 2008; Chen et al., 2017). 
However, there are apparently opposite results related to hypertrophy development that might 
appear together with this cardiac dysfunction. Thus, some authors have described Nfx-induced 
cardiac dysfunction with a significant increment of the heart weight (Chen et al., 2017) while 
other authors using the same experimental CKD model did not observe any increase in the 
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heart weight (Bro, Bollano, Brüel, Olgaard & Nielsen, 2008) as we have also observed in the 
present study. These apparently opposite results could be explained by the age of the animals 
used and also the time employed from 5/6 Nfx surgery to the cardiac analysis. In our hands, 
this experimental model of CKD developed a dysfunctional cardiac phenotype without 
hypertrophy or fibrosis development. This is an ideal in vivo model to study functional cardiac 
events such as heart failure and the predisposition to arrhythmia related to Ca2+ mishandling in 
the context of uraemic cardiomyopathy without any overlap due to structural myocardial 
alterations. Using this model, we demonstrate a cardioprotective role of klotho through the 
normalisation of cardiomyocyte Ca2+ cycling. Mechanistically, we propose that RyRs are a 
novel target of klotho, and klotho could act as a “brake” for the pro-arrhythmogenic Ca2+ leak 
from the SR by impeding phosphorylation and hyperactivation of RyRs previously observed 
in CKD. By halting Ca2+ leakage, klotho helps to maintain an adequate cellular shortening due 
to the recovery of systolic Ca2+ release in the form of Ca2+ transients and, at the same time, 
impedes the increase in diastolic Ca2+ release in the form of Ca2+ sparks or waves that might 
favour reaching a intracellular Ca2+ threshold able to evoke automatic Ca2+ transients and 
extracontractions. Finally, one of the most relevant findings of our study is that we show for 
the first time that klotho can protect the heart from Ca2+ mishandling associated with CKD 
without any associated improvement in renal dysfunction. Thus, Nfx mice overexpressing 
klotho or chronically treated with rKL present the same high systemic levels of FGF-23 and 
BUN as those Nfx mice treated with vehicle. We believe these findings are clinically relevant 
because strategies directed to maintain adequate klotho levels could be a new therapeutic goal 
to directly protect the heart from a uraemic environment and guaranteeing FGF-23 
phosphaturic action.   
One limitation of the present study is the lack of data in larger animal models that exhibit closer 
physiological characteristics to humans, such as rabbits or pigs. Moreover, further investigation 
will be required to determine in-depth whther the klotho deficiency, a very common aspect in 
CKD patients, might influence diastolic Ca2+ levels and therefore compromise cardiac 
contractility. We envision the need to corroborate the cardioprotective role of klotho 
throughout the development of renal disease from initial stages including in larger animal 
models in future studies.  
Conclusion  
This study provides new insights into how klotho availability determines cardiac function in 
uraemic cardiomyopathy via regulation of Ca2+ handling. The present investigation revealed 
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the dysregulated cardiac physiological mechanisms in uraemia modelled by klotho deficiency 
or nephrectomy, including defects in systolic Ca2+ release and contractile dysfunction together 
with RyR hyperactivation, which can explain the elevated presence of pro-arrhythmogenic 
Ca2+ events found in a uraemic setting. All of these alterations in Ca2+ handling observed in 
CKD mice were prevented when klotho was present, indicating that therapeutic strategies 
directed to improve klotho availability might be good candidates to protect the heart from 
cardiac dysfunction and arrhythmogenic potential events in CKD.  
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Figure 1. Klotho deficiency impairs systolic Ca2+ release and induces contractile 
dysfunction. (A) Appearance of 7-week-old wild-type (+/+) mouse and its Klotho-
hypomorphic (kl/kl) littermate. (B) Line-scan images and fluorescence profiles of 
cardiomyocytes under 2 Hz field stimulation. (C&D) Mean values of peak (F/F0) (C) and time 
of decay (Tau) (D) of electrically-evoked Ca2+ transients in +/+ (n=50 cells/N=5 mice) and 
kl/kl (n=49 cells/N=5 mice). (E) Cell shortening profiles of cardiomyocytes. (F) Percentage of 
cell contraction of +/+ (n=50 cells/N=5 mice) and kl/kl (n=49 cells/N=5 mice). Data are shown 
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Figure 2. Klotho deficiency reduces SR-Ca2+ load and increases diastolic Ca2+ leak and 
pro-arrhythmogenic events. (A) Line-scan images of cardiomyocytes under 2 Hz field 
stimulation perfused with caffeine. (B) Mean values of caffeine-evoked Ca2+ transients 
amplitude expressed as peak (F/F0) in +/+ (n=31 cells/N=5 mice) and kl/kl (n=39 cells/N=5 
mice). (C) Line-scan images of spark recordings in quiescent cardiomyocytes. (D) Mean values 
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of Ca2+ spark frequency in +/+ (664 sparks, n=48 cells/N=5 mice) and kl/kl (630 sparks, n=39 
cells/N=5 mice). (E) Line-scan images of spontaneous Ca2+ release (SCR) as spontaneous Ca2+ 
transients (left panel) or Ca2+ waves  (right panel) in quiescent kl/kl cardiomyocytes.  (F) 
Occurrence of SCR in +/+ (n=48 cells/N=5 mice) and kl/kl (n=39 cells/N=5 mice). (G) Line-
scan images and fluorescence profiles of cardiomyocytes paced at 2 Hz field stimulation. (H) 
Occurrence of pro-arrhythmogenic events related to automatic Ca2+ transients and automatic 
contractions in +/+ (n=26 cells/ N= 5 mice) and kl/kl (n=38 cells/N=5 mice) mice. Data are 
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Figure 3. Recombinant klotho prevents contractile cellular dysfunction and reduction in 
systolic Ca2+. (A) Schematic design of CKD animal model (5/6 nephrectomy) and treatments. 
(B) Mean values of ejection fraction (EF) from Sham (N=5 mice), Nfx (N=5 mice), Sham+rKL 
(N=5 mice) and Nfx+rKL (N=5 mice) mouse hearts. (C) Cell shortening profiles of 
cardiomyocytes. (D) Percentage of cell contraction of Sham (n=52 cells/N=5 mice), Nfx (n=73 
cells/N=6 mice), Sham+rKL (n=62 cells/N=5 mice) and Nfx+rKL (n=48 cells/N=6 mice). (E) 
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Line-scan images and fluorescence profiles of cardiomyocytes under 2 Hz field stimulation. 
(F&G) Mean values of peak (F/F0) (F) and time of decay (Tau) (G) of electrically-evoked Ca
2+ 
transients in Sham (n=54 cells/N=5 mice), Nfx (n=77 cells/N=6 mice), Sham+rKL (n=67 
cells/N=5 mice) and Nfx+rKL (n=49 cells/N=6 mice). Data shown mean±SEM. *P<0.05 vs. 
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Figure 4. Recombinant klotho prevents SR-Ca2+ load and diastolic SR-Ca2+ leak in 
experimental CKD. (A) Line-scan images of cardiomyocytes under 2 Hz field stimulation 
perfused with caffeine. (B) Mean values of caffeine-evoked Ca2+ transients amplitude 
expressed as peak (F/F0) in Sham (n=66 cells/N=6 mice), Nfx (n=79 cells/N=6 mice), 
Sham+rKL (n=67 cells/N=6 mice) and Nfx+rKL (n=49 cells/N=6 mice) cardiomyoyctes. (C) 
Line-scan images of spark recordings in quiescent cardiomyocytes. (D) Mean values of Ca2+ 
spark frequency in Sham (1270 sparks, n=42 cells/N=5 mice), Nfx (2985 sparks, n=55 
cells/N=6 mice), Sham+rKL (1188 sparks, n=56 cells/N=5 mice) and Nfx+rKL (1075 sparks, 
n=39 cells/N=6 mice). (E) Line-scan images of spontaneous Ca2+ release (SCR) as Ca2+ waves 
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(left panel) or spontaneous Ca2+ transients (right panel) in quiescent Nfx cardiomyocytes. (F) 
Occurrence of SCR in Sham (n=42 cells/N=5 mice), Nfx (n=55 cells/N=6 mice), Sham+rKL 
(n=56 cells/N=5 mice) and Nfx+rKL (n=39 cells/N=6 mice) cardiomyocytes. Data are shown 
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Figure 5. Recombinant klotho treatment impedes pro-arrhythmogenic events induced by 
Nfx. (A) Line-scan images and fluorescence profiles of cardiomyocytes paced at 2 Hz field 
stimulation. (B) Occurrence of pro-arrhythmogenic events related to automatic Ca2+I transients 
and automatic contractions in Sham (n=92 cells/N= 5 mice), Nfx (n=142 cells/N=6 mice), 
Sham+rKL (n=72 cells/N=5 mice) and Nfx+rKL (n=149 cells/N=7 mice) mice. Data are shown 








Figure 6. Recombinant klotho protects against RyR hyperactivation in experimental 
CKD. (A-B) Specific [3H]-Ryanodine binding at (A) 10 µM (equivalent to the intracellular 
Ca2+ rise in systole) and (B) 100 nM (equivalent to basal levels of intracellular Ca2+ in quiescent 
conditions or diastole) and free Ca2+ concentrations of heart homogenates from Sham (N=5 
mice), Nfx (N=5 mice), Sham+rKL (N=7 mice) and Nfx+rKL (N=6 mice). [3H]-Ryanodine 
binding values were normalised to the specific [3H]-Ryanodine binding at 100 µM free [Ca2+].  
(C-D) Western blots (upper panels) and quantification (bottom panels) of RyR phosphorylation 
at Ser2030 (p-RyR2030) or at Ser2814 (p-RyR2814) normalised to total RyR from Sham (N=5 mice), 
Nfx (N=7 mice), Sham+rKL (N=5 mice) and Nfx+rKL (N=7 mice) hearts. Data are shown as 
mean±SEM. *P<0.05 vs. Sham; #P<0.05 vs. Nfx.  
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Figure 7. Klotho overexpression protects from electrical cardiac and Ca2+ cycling 
alterations induced by CKD. (A-C) Mean serum levels of (A) blood urea nitrogen (BUN), 
(B) phosphates (Pi) and (C) FGF-23 in Sham-Tg-Kl (N=5 mice) and Nfx-Tg-Kl (N=5 mice). 
(D) Mean values of Ca2+ sparks frequency in Sham-Tg-Kl (995 sparks, n=54 cells/N=5 mice), 
Nfx-Tg-Kl (893 sparks, n=55 cells/N=6 mice). (E) Occurrence of SCR in Sham-Tg-Kl (n=54 
cells/N=5 mice), Nfx-Tg-Kl (n=55 cells/N=6 mice). (F) Mean values of caffeine-evoked Ca2+ 
transients amplitude expressed as peak (F/F0) in Sham-Tg-Kl (n=40 cells/N=5 mice), Nfx-Tg-
Kl (n=34 cells/N=6 mice). (G) Mean values of peak (F/F0) of electrically-evoked Ca
2+ 
transients in Sham-Tg-Kl (n=64 cells/N=5 mice), Nfx-Tg-Kl (n=55 cells/N=6 mice) (H) 
Percentage of cell contraction of Sham-Tg-Kl (n=56 cells/N=5 mice) and Nfx-Tg-Kl (n=52 
cells/N=6 mice). Data are shown as mean±SEM. *P<0.05 vs. Sham-Tg-Kl.  
